A Practical Guide for Using Registry Data to Inform Decisions About the Cost Effectiveness of New Cancer Drugs: Lessons Learned from the PHAROS Registry
Open Access
- 3 February 2015
- journal article
- research article
- Published by Springer Nature in PharmacoEconomics
- Vol. 33 (6) , 551-560
Abstract
Decision makers increasingly request evidence on the real-world cost effectiveness of a new treatment. There is, however, a lack of practical guidance on how to conduct an economic evaluation based on registry data and how this evidence can be used in actual decision making. This paper explains the required steps on how to perform a sound economic evaluation using examples from an economic evaluation conducted with real-world data from the Dutch Population based HAematological Registry for Observational Studies. There are three main issues related to using registry data: confounding by indication, missing data, and insufficient numbers of (comparable) patients. If encountered, it is crucial to accurately deal with these issues to maximize the internal validity and generalizability of the outcomes and their value to decision makers. Multivariate regression modeling, propensity score matching, and data synthesis are well-established methods to deal with confounding. Multiple imputation methods should be used in cases where data are missing at random. Furthermore, it is important to base the incremental cost-effectiveness ratio of a new treatment compared with its alternative on comparable groups of (matched) patients, even if matching results in a small analytical population. Unmatched real-world data provide insights into the costs and effects of a treatment in a real-world setting. Decision makers should realize that real-world evidence provides extremely valuable and relevant policy information, but needs to be assessed differently compared with evidence derived from a randomized clinical trial.Keywords
This publication has 31 references indexed in Scilit:
- Practical feasibility of outcomes research in oncology: Lessons learned in assessing drug use and cost-effectiveness in The NetherlandsEuropean Journal of Cancer, 2012
- Application of Cost–Effectiveness Analysis to Demonstrate the Potential value of Companion Diagnostics in Chronic Myeloid LeukemiaPharmacogenomics, 2011
- Modelling Methods for Pharmacoeconomics and Health Technology AssessmentPharmacoEconomics, 2008
- Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in SwedenActa Oncologica, 2008
- The impact of follicular lymphoma on health-related quality of lifeAnnals of Oncology, 2007
- Understanding the limited impact of economic evaluation in health care resource allocation: A conceptual frameworkHealth Policy, 2007
- A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methodsJournal of Clinical Epidemiology, 2006
- Good Practice Guidelines for Decision-Analytic Modelling in Health Technology AssessmentPharmacoEconomics, 2006
- Results of Multivariable Logistic Regression, Propensity Matching, Propensity Adjustment, and Propensity-based Weighting under Conditions of Nonuniform EffectAmerican Journal of Epidemiology, 2005
- The central role of the propensity score in observational studies for causal effectsBiometrika, 1983